Search by Tag: CRO
107 total news stories found.
Solid-State Chemistry Services CRO, Onyx Scientific Reports Increased Demand for Polymorph Screening, Salt Selection and Crystallization Studies
2010-11-10 | Onyx Scientific's global customer base outsource to access Onyx's world-class GMP chemistry expertise. Onyx deliver "one partner" convenience with pre-agreed workflows tailored to support key analytical milestones and timescales.
Pharmatech Oncology, Inc.
2010-10-21 | Pharmatech Oncology announces an abstract supported by the company has been accepted for presentation during the 52nd annual American Society of Hematology (ASH) meeting in Orlando, FL, December 4-7, 2010.
ensur's Document Control Software Celebrates the End of its Explosive Summer Expansion
2010-10-05 | Mystic Management Systems' ensur Document Control Software has been selected as their choice for quality process enhancement by Athersys of Ohio and Cambridge Polymer Group out of Massachusetts.
GMP Synthesis Chemistry Services CRO, Onyx Scientific, Reports Increased Small Scale Production for Phase I and II Clinical Studies
2010-09-04 | Onyx Scientific manufacture high value intermediates and APIs to GMP-compliant standards for both phase I and phase II clinical studies.
Polymorph Screening Chemistry Services CRO, Onyx Scientific, Announces the Continued Strong Growth of its Solid-State Services
2010-07-08 | Onyx Scientific provides polymorph screening throughout all stages of a drug-discovery process. Onyx solid-state services include: salt selection; physicochemical property determinations and crystallisation studies.
UFC 110 Odds See A Major Change As Bettors Flock To Cain Velasquez
2010-02-18 | The Vegas betting odds for UFC 110 "Nogueira vs. Velasquez" have shifted drastically and now have been updated and released to the public
BioScience Laboratories, Inc. and Synomics Pharmaceutical Services Announce Their Partnership to Provide Phase 1 Clinical Study Services
2009-10-10 | BioScience Laboratories, Inc. and Synomics Pharmaceutical Services announced today their formal partnership to provide a fully integrated phase 1 clinical study capability for trials in healthy human subjects.